Pure Global AI
NCT06233474Recruiting

Study of Intra-articular Allocetra in Knee Osteoarthritis

A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis
Enlivex Therapeutics Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Osteoarthritis, Knee
Drug/Device/Intervention
Allocetra
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Enlivex Therapeutics Ltd.
Location
Afula,Haifa,Petach Tikva,Reẖovot, Israel
Timeline & enrollment
Phase
Phase 1/2
Start date
Jan 26, 2024
End date
Feb 01, 2026
Enrollment
160 participants
Primary outcome

Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection

Summary

This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of
 intra-articular administration of Allocetra compared to placebo in patients with symptomatic
 knee osteoarthritis.

ICD-10 classifications
Chronic instability of kneeInjuries to the knee and lower legGonarthrosis [arthrosis of knee]Dislocation, sprain and strain of joints and ligaments of kneeSprain and strain of other and unspecified parts of knee
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06233474
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06233474 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Enlivex Therapeutics Ltd. and is currently Recruiting. The study focuses on Osteoarthritis, Knee. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.